Skip to main content

Advertisement

SpringerLink
Log in

Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management

  • Cardio-oncology (M Fradley, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Pulmonary hypertension is caused by cancer and its therapeutic agents including chemotherapy, radiotherapy, and even the targeted therapies. Ironically, some of the cancer therapies that cause one type of pulmonary hypertension (PH) could potentially be employed in the treatment of another PH type. Greater awareness on the role of cancer therapeutic agents in causing PH is required. Conversely, since PH is mostly incurable, the potential role of some of these cancer therapeutic agents in the cure of PH should be recognized. In short, the relationship between cancer, cancer therapy, and PH is an interesting one requiring further attention, education, and research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50. Up-to-date findings and recommendations on the definition and diagnosis of PH presented in the Fifth World Symposium on PH

    Article  PubMed  Google Scholar 

  2. •• Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177. Consensus guidelines update for the classification of PH adopted from the Fifth World Symposium on Pulmonary Hypertension

    Article  Google Scholar 

  3. • McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97. A review article that provides an overview of the generally accepted management strategies for patients with PH in the context of recently published studies in the area

    Article  PubMed  Google Scholar 

  4. Rai PR, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:558–64.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Delom F, et al. Pulmonary arterial hypertension and cancer: an update on their similarities. Ann Res Rev Biol. 2014;4(1):20–37.

    Article  Google Scholar 

  6. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219–63.

    Article  PubMed  Google Scholar 

  7. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465–72.

    Article  CAS  PubMed  Google Scholar 

  8. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–20.

    Article  PubMed  Google Scholar 

  9. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–21. Review

    PubMed  Google Scholar 

  10. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.

    Article  PubMed  Google Scholar 

  11. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349(2):109–11.

    Article  CAS  PubMed  Google Scholar 

  12. Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325–31.

    Article  CAS  PubMed  Google Scholar 

  13. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601–8.

    Article  PubMed  Google Scholar 

  14. Mandelstamm M. Über primäre Neubildungen des Herzens. Virchows Arch. 1923;245:43–54.

    Article  Google Scholar 

  15. Blackmon SH, Rice DC, Correa AM, Mehran R, Putnam JB, Smythe WR, et al. Management of primary pulmonary artery sarcomas. Ann Thorac Surg. 2009;87:977–84.

    Article  PubMed  Google Scholar 

  16. Mussot S, Ghigna MR, Mercier O, Fabre D, Fadel E, Le Cesne A, et al. Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. Eur J Cardiothorac Surg. 2013;43:787–93.

    Article  PubMed  Google Scholar 

  17. Wong HH, Gounaris I, McCormack A, et al. Presentation and management of pulmonary artery sarcoma. Clinical Sarcoma Research. 2015;5:3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 2008;4.

  19. Dasanu CA, Codreanu I, Mesologites T, Ali S, Sullivan P, Jethava A. Western variant of brain intravascular lymphoma displaying three distinct evolutive radiologic stages. Conn Med. 2014;78(2):73–6.

    PubMed  Google Scholar 

  20. Walls JG, Hong YG, Cox JE, et al. Pulmonary intravascular lymphomatosis: presentation with dyspnea and air trapping. Chest. 1999;115:1207–10.

    Article  CAS  PubMed  Google Scholar 

  21. Sinha N, Lantigua L, Niazi M, et al. An elderly lady with fever of unknown etiology and severe pulmonary hypertension: intravascular lymphoma-an elusive diagnosis. Case Rep Med. 2013;2013:153798.

    PubMed  PubMed Central  Google Scholar 

  22. Snyder LS, Harmon KR, Estensen RD. Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension. Chest. 1989;96(5):1199–200.

    Article  CAS  PubMed  Google Scholar 

  23. Aouba A, Diop S, Saadoun D, et al. Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: case report. Am J Hematol. 2005;79:46–9.

    Article  PubMed  Google Scholar 

  24. Kotake T, Kosugi S, Takimoto T, Nakata S, Shiga J, Nagate Y, Nakagawa T, Take H, Katagiri S. Intravascular large B-cell lymphoma presenting pulmonary arterial hypertension as an initial manifestation. Intern Med. 2010;49(1):51–4.

    Article  PubMed  Google Scholar 

  25. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27:1056–65.

    CAS  PubMed  Google Scholar 

  26. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133:507–16.

    Article  CAS  PubMed  Google Scholar 

  27. Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev. 2011;20:34–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151:527–33.

    Article  CAS  PubMed  Google Scholar 

  29. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d’Etudes et de Recherche sur les maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore). 1999;78:321–37.

    Article  CAS  Google Scholar 

  30. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999;115:1041–52.

    Article  CAS  PubMed  Google Scholar 

  31. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105–11.

    Article  PubMed  Google Scholar 

  32. Cottin V, Archer F, Leroux C, et al. Milestones in lymphangioleiomyomatosis research. Eur Respir Rev. 2011;20:3–6.

    Article  CAS  PubMed  Google Scholar 

  33. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012;40:630–40.

    Article  PubMed  Google Scholar 

  34. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest. 2007;132:1573–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277:30958–67.

    Article  CAS  PubMed  Google Scholar 

  36. Krymskaya VP, Snow J, Cesarone G, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 2011;25:1922–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593–604.

    Article  CAS  PubMed  Google Scholar 

  38. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5(6):477–85.

    Article  CAS  PubMed  Google Scholar 

  39. Cawthon RM, Weiss R, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990;62:193–201.

    Article  CAS  PubMed  Google Scholar 

  40. Cawthon RM, O'Connell P, Buchberg AM, et al. Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics. 1990;7:555–65.

    Article  CAS  PubMed  Google Scholar 

  41. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187–92.

    Article  CAS  PubMed  Google Scholar 

  42. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181–6.

    Article  CAS  PubMed  Google Scholar 

  43. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597–601.

    Article  CAS  PubMed  Google Scholar 

  44. Wild A, Kalff-Suske W, Vortkamp A, et al. Point mutations in human GLI3 cause Greig syndrome. Hum Mol Genet. 1997;6:1979–84.

    Article  CAS  PubMed  Google Scholar 

  45. Norton KK, Xu J, Gutmann DH. Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis. 1995;2(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  46. Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet. 2000;58(5):341–4.

    Article  CAS  PubMed  Google Scholar 

  47. Montani D, Coulet F, Girerd B, Eyries M, Bergot E, Mal H, Biondi G, Dromer C, Hugues T, Marquette C, O'Connell C, O'Callaghan DS, Savale L, Jaïs X, Dorfmüller P, Begueret H, Bertoletti L, Sitbon O, Bellanné-Chantelot C, Zalcman G, Simonneau G, Humbert M, Soubrier F. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore). 2011;90(3):201–11.

    Article  Google Scholar 

  48. Samuels N, Berkman N, Milgalter E, Bar-Ziv J, Amir G, Kramer MR. Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Thorax. 1999;54:858–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Stewart DR, Cogan JD, Kramer MR, Miller Jr WT, Christiansen LE, Pauciulo MW, Messiaen LM, Tu GS, Thompson WH, Pyeritz RE, Ryu JH, Nichols WC, Kodama M, Meyrick BO, Ross DJ. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest. 2007;132:798–808.

    Article  PubMed  Google Scholar 

  50. Miyano S, Izumi S, Takeda Y, Tokuhara M, Mochizuki M, Matsubara O, et al. Pulmonary tumor thrombotic microangiopathy. J Clin Oncol. 2007;25:597–9.

    Article  PubMed  Google Scholar 

  51. Godbole R, Ghatol A, Betancourt J, Sacoolidge J, Kamangar N. Pulmonary tumor thrombotic Microangiopathy: clinical, radiologic, and histologic correlation. Journal of Clinical Imaging Science. 2015;5:44.

    Article  PubMed  PubMed Central  Google Scholar 

  52. von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990;66:587–92.

    Article  Google Scholar 

  53. Uruga H, Fujii T, Kurosaki A, Hanada S, Takaya H, Miyamoto A, et al. Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med. 2013;52:1317–23.

    Article  PubMed  Google Scholar 

  54. Kayatani H, Matsuo K, Ueda Y, Matsushita M, Fujiwara K, Yonei T, et al. Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy. Intern Med. 2012;51:2767–70.

    Article  PubMed  Google Scholar 

  55. Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G. Baccarani M; GIMEMA acute leukemia working party.. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8.

    Article  PubMed  Google Scholar 

  56. Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32:1354–65. Leukemia. Blood. 2011;118:6521–6528

    Article  CAS  PubMed  Google Scholar 

  57. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–37.

    Article  CAS  PubMed  Google Scholar 

  58. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060–4.

    Article  CAS  PubMed  Google Scholar 

  59. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99–105.

    Article  PubMed  Google Scholar 

  60. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967–8.

    Article  CAS  PubMed  Google Scholar 

  61. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165–72.

    Article  CAS  PubMed  Google Scholar 

  62. Siegel D, Martin T, Nooka A, et al. Integrated saferty profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jaïs X, Sitbon O, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356–71.

    Article  CAS  PubMed  Google Scholar 

  64. Nicod P, Moser KM. Primary pulmonary hypertension: the risk and benefit of lung biopsy. Circulation. 1989;80:1486–8.

    Article  CAS  PubMed  Google Scholar 

  65. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, Tchérakian C, Rabiller A, Haque R, Sitbon O, Jaïs X, Dartevelle P, Maître S, Capron F, Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87:220–33.

    Article  Google Scholar 

  66. Perros F, Cohen-Kaminsky S, Gambaryan N, Girerd B, Raymond N, Klingelschmitt I, Huertas A, Mercier O, Fadel E, Simonneau G, Humbert M, Dorfmüller P, Montani D. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2013;187:189e196.

    Article  Google Scholar 

  67. Hoorn CM, Wagner JG, Petry TW, Roth RA. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol. 1995;130:87e94.

    Article  Google Scholar 

  68. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamidemediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570e1574. 38

    Article  Google Scholar 

  69. Ohtani T, Nakamura T, Toda K-I, Furukawa F. Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett. 2006;580:1597e1600.

    Article  Google Scholar 

  70. Cooper Jr JA, Merrill WW, Reynolds HY. Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism: possible mechanisms of pulmonary pharmacotoxicity. Am Rev Respir Dis. 1986;134:108e114. 37

    Article  Google Scholar 

  71. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24:830e837. 40

    Article  Google Scholar 

  72. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574e1577.

    Article  Google Scholar 

  73. •• Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët D-A, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65e69. By using whole-exome sequencing, this study detected recessive mutations in EIF2AK4 (also called GCN2) that cosegregated with PVOD in 13 families studied. These findings point to EIF2AK4 as the major gene that is linked to PVOD development

    Google Scholar 

  74. Kramer MR, Estenne M, Berkman N, Antoine M, de Francquen P, Lipski A, Jacobovitz D, Lafair J. Radiation-induced pulmonary venoocclusive disease. Chest. 1993;104:1282e1284.

    Article  Google Scholar 

  75. Ghobadi G, Bartelds B, van der Veen SJ, Dickinson MG, Brandenburg S, Berger RM, Langendijk JA, Coppes RP, van Luijk P. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax. 2012;67:334–41.

    Article  CAS  PubMed  Google Scholar 

  76. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant. 1996;18:755–60.

    CAS  PubMed  Google Scholar 

  77. Kuga T, Kohda K, Hirayama Y, Matsumoto S, Nakazawa O, Ando M, Ezoe A, Nobuoka A, Mochizuki C. Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol. 1996;64:143–50.

    Article  CAS  PubMed  Google Scholar 

  78. Troussard X, Bernaudin JF, Cordonnier C, Fleury J, Payen D, Briere J, Vernant JP. Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax. 1984;39:956–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant. 2008;41:677–86.

    Article  CAS  PubMed  Google Scholar 

  80. Gottlieb, Roberta, and Puja Mehta (2016). Pulmonary Hypertension and Cancer. In: Cardio-oncology Principles, Prevention and Management (pp273–282). Elsevier Science.

  81. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

    Article  CAS  PubMed  Google Scholar 

  82. Vachiery JL, Adir Y, Barbera JA, Champion HC, Coghlan JG, Cottin V, DeMarco T, Galiè N, Ghio S, Gibbs JS, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Seeger W. Pulmonary hypertension due to left heart disease. J Am Coll Cardiol. 2013;62:D100–8.

    Article  PubMed  Google Scholar 

  83. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the pulmonary hypertension Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2012;31:913–33.

    Article  PubMed  Google Scholar 

  84. • Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62:D92–9. Up-to-date findings and recommendations on new diagnostic and treatment algorithms for Chronic Thromboembolic Pulmonary Hypertension presented in the Fifth Wolrd Symposium on PH

    Article  PubMed  Google Scholar 

  85. Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ. 2011;1(2):138–59.

    Article  PubMed  PubMed Central  Google Scholar 

  86. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. J Am Coll Cardiol. 2009;53:1573–619.

    Article  PubMed  Google Scholar 

  87. Galiè N, Ghofrani AH. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22(130):503–14.

    Article  PubMed  Google Scholar 

  88. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twentythree cases. Arthritis Rheum. 2008;58:521–31.

    Article  PubMed  Google Scholar 

  89. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002;346:683–93.

    Article  CAS  PubMed  Google Scholar 

  90. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. • Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, Le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phrase treated with imitinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–5. A retrospective cohort analysis from three randomized phase III studies revealed lower incidence of cardiovascular events in patients treated with imatinib compared with patients not treated with TKI or patients treated with nilotinib. This study suggested that imatinib may be inherently protective against vascular events

    Article  CAS  PubMed  Google Scholar 

  92. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412–3.

    Article  CAS  PubMed  Google Scholar 

  93. • Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127:1128–38. A 24-week randomized, double-blind, placebo-controlled trial showed that imatinib therapy could improve cardiac output with a modest reduction in mPAP in patients with severe pulmonary arterial hypertension despite therapy with at least two standard PAH drugs

    Article  CAS  PubMed  Google Scholar 

  94. Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015;34(11):1366–75.

    Article  PubMed  Google Scholar 

  95. Wang X, Ibrahim YF, Das D, Zungu-Edmondson M, Shults NV, Suzuki YJ. Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res. 2016;110(2):188–99.

    Article  PubMed  Google Scholar 

  96. Suzuki YJ, Ibrahim YF, Shults NV. Apoptosis-based therapy to treat pulmonary arterial hypertension. Journal of rare diseases research & treatment. 2016;1(2):17–24.

    Google Scholar 

  97. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, Fedullo PF, Jamieson SW. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97–103.

    Article  PubMed  Google Scholar 

  98. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E, Klein A, Arrowsmith J, Hall R, Jenkins D. Circulatory arrest versus cerebral perfu- sion during pulmonary endarterectomy surgery (PEACOG): a randomised con- trolled trial. Lancet. 2011;378:1379–87.

    Article  PubMed  Google Scholar 

  99. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Sur- gical management and outcome of patients with chronic thromboembolic pul- monary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702–10.

    Article  PubMed  Google Scholar 

  100. Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic thrombo- embolic pulmonary hypertension diagnosis and management. Eur Respir Rev. 2012;21:32–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Rush University Medical Center, 1717 W. Congress Parkway, 1042 Kellogg, Chicago, IL, 60612, USA

    Fatima A. Ballout MD & Ahmad S. Manshad MD

  2. Department of Internal Medicine-Cardiology, Rush University Medical Center, Chicago, IL, USA

    Tochukwu M. Okwuosa DO

Authors
  1. Fatima A. Ballout MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmad S. Manshad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tochukwu M. Okwuosa DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tochukwu M. Okwuosa DO.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ballout, F.A., Manshad, A.S. & Okwuosa, T.M. Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management. Curr Treat Options Cardio Med 19, 44 (2017). https://doi.org/10.1007/s11936-017-0543-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-017-0543-5

Keywords

Search

Navigation